wire - news in brief
Health - Dec 14
Microtechnics - Dec 12
A research team from the University of Zurich and EPFL have developed a new drone that can retract its propeller arms in flight and make itself small to fit through narrow gaps and holes.
Life Sciences - Dec 12
Although wastewater treatment plants (WWTPs) remove over 95 per cent of human fecal bacteria, many resistant bacteria can still be detected in the final effluent.
Category
Results 1 - 50 of 367.
Novartis receives European Commission approval for self-administration of Xolair across all indications
The EC approval underscores the long-term safety and efficacy of Xolair demonstrated in clinical studies and by 13 years of real-world use in Europe Xolair (omalizumab) prefilled syringe (PFS) is t
The EC approval underscores the long-term safety and efficacy of Xolair demonstrated in clinical studies and by 13 years of real-world use in Europe Xolair (omalizumab) prefilled syringe (PFS) is t
Mario Botta: "I'd like to create a monastery"
Throughout his 50-year-long career, architect Mario Botta has seen his profession undergo profound change, from the introduction of modern styles to the advent of post-modernism.
Throughout his 50-year-long career, architect Mario Botta has seen his profession undergo profound change, from the introduction of modern styles to the advent of post-modernism.
Sandoz Inc. and Pear Therapeutics Obtain FDA Clearance for reSET-O(TM) to Treat Opioid Use Disorder
ReSET-O TM is the first FDA-cleared Prescription Digital Therapeutic (PDT) for patients with Opioid Use Disorder Pear Therapeutics is leading the development of a new therapeutic class with two FDA-a
ReSET-O TM is the first FDA-cleared Prescription Digital Therapeutic (PDT) for patients with Opioid Use Disorder Pear Therapeutics is leading the development of a new therapeutic class with two FDA-a
Reserve your driving time to reduce traffic congestion
For his thesis, EPFL PhD student Raphaël Lamotte studied rush-hour traffic congestion. He suggests implementing a system whereby commuters reserve time on a special traffic lane - like booking a seat on a flight - to help cities accommodate a growing number of car-sharing programs and, eventually, self-driving cars.
For his thesis, EPFL PhD student Raphaël Lamotte studied rush-hour traffic congestion. He suggests implementing a system whereby commuters reserve time on a special traffic lane - like booking a seat on a flight - to help cities accommodate a growing number of car-sharing programs and, eventually, self-driving cars.
Highlighting diversity, arousing fascination and raising awareness of the vital tasks that insects perform in nature.
Novartis data demonstrates consistent efficacy and tolerability of Kisqali combination therapy in HR+/HER2- advanced breast cancer in patients with difficult-to-treat visceral disease
Subgroup analyses of three pivotal Phase III MONALEESA trials showed Kisqali plus endocrine therapy extended PFS in all patients with and without visceral involvement compared to endocrine therapy
Subgroup analyses of three pivotal Phase III MONALEESA trials showed Kisqali plus endocrine therapy extended PFS in all patients with and without visceral involvement compared to endocrine therapy
A new EU regulation that went into effect in May has prompted consumers to pay more attention to how websites use the personal data they collect. With Polisis, an AI-based program developed at EPFL, consumers can get quick, easy-to-read summaries of websites' data protection policies. And the program is becoming highly popular - EPFL's Technology Transfer Office has received numerous license requests.
FDA approves Roche’s Tecentriq in combination with Avastin and chemotherapy for the initial treatment of people with a specific type of metastatic lung cancer
Approval based on survival benefit of Tecentriq in combination with Avastin, paclitaxel and carboplatin (chemotherapy) in people with metastatic non-squamous non-small cell lung cancer (NSCLC) with n
Approval based on survival benefit of Tecentriq in combination with Avastin, paclitaxel and carboplatin (chemotherapy) in people with metastatic non-squamous non-small cell lung cancer (NSCLC) with n
EU grants 14 million to Swiss Researchers
Fuelling the next quantum revolution with the research project HERO An ERC Grant is the most prestigious award for excellent European research projects. A team with three researchers from the ETH Domain had also applied for such a grant. Today, Gabriel Aeppli from the Paul Scherrer Institute PSI, Henrik Rønnow from the Swiss Federal Institute of Technology Lausanne EPFL and Nicola Spaldin from ETH Zurich, together with their colleague Alexander Balatsky from Nordita, Stockholm University, received the contract signed by the EU confirming the extraordinary 14 million euro funding.
Fuelling the next quantum revolution with the research project HERO An ERC Grant is the most prestigious award for excellent European research projects. A team with three researchers from the ETH Domain had also applied for such a grant. Today, Gabriel Aeppli from the Paul Scherrer Institute PSI, Henrik Rønnow from the Swiss Federal Institute of Technology Lausanne EPFL and Nicola Spaldin from ETH Zurich, together with their colleague Alexander Balatsky from Nordita, Stockholm University, received the contract signed by the EU confirming the extraordinary 14 million euro funding.
Four of the highly-regarded "ERC Consolidator Grants", the research prizes of the European Research Council (ERC), have been awarded to researchers at the University of Bern.
EPFL part of Europe's largest research initiative on urban mobility
The MOBiLus consortium, made up of nearly 50 organizations including EPFL, has just won major EU financing to study new approaches to urban transportation.
The MOBiLus consortium, made up of nearly 50 organizations including EPFL, has just won major EU financing to study new approaches to urban transportation.
Roche’s Kadcyla cut the risk of disease recurring by half compared to Herceptin in people with HER2-positive early breast cancer with residual disease after neoadjuvant treatment
At three years, 88.3% of people treated with Kadcyla in the adjuvant HER2-positive early breast cancer setting did not have their breast cancer return compared to 77.0% treated with Her
At three years, 88.3% of people treated with Kadcyla in the adjuvant HER2-positive early breast cancer setting did not have their breast cancer return compared to 77.0% treated with Her
FDA grants priority review to Roche’s Tecentriq in combination with chemotherapy for the initial treatment of extensive-stage small cell lung cancer
Roche today announced that the US Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License Application (sBLA) and granted Priority Review for Tecentriq (atezolizum
Roche today announced that the US Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License Application (sBLA) and granted Priority Review for Tecentriq (atezolizum
In a new book, EPFL researchers trace the history of La Buvette d'Evian - a former lakeside refreshment area that is also an icon of modern architecture. With some light renovation work, La Buvette could reinvigorate the entire region. The book launch will take place on 6 December at EPFL. For over 40 years, tourists and people with kidney ailments came to La Buvette d'Evian for the healing properties of the region's water.
Novartis advances ligelizumab (QGE031) in urticaria to Phase III on basis of strong Phase II head-to-head data
PEARL 1 and PEARL 2, the largest pivotal trials to date in chronic spontaneous urticaria (CSU), will enroll more than 2,000 CSU patients , Ligelizumab (QGE031), a monoclonal antibody, is being deve
PEARL 1 and PEARL 2, the largest pivotal trials to date in chronic spontaneous urticaria (CSU), will enroll more than 2,000 CSU patients , Ligelizumab (QGE031), a monoclonal antibody, is being deve
New Venclexta/Venclyxto data demonstrate deep responses in two of the most common types of leukaemia
New analyses from the phase III MURANO study in previously treated chronic lymphocytic leukaemia show continued benefit from fixed-duration regimen after a median follow-up of three years Updated res
New analyses from the phase III MURANO study in previously treated chronic lymphocytic leukaemia show continued benefit from fixed-duration regimen after a median follow-up of three years Updated res
Roche’s Hemlibra provided sustained bleed control in the largest pivotal study to date of children with haemophilia A with factor VIII inhibitors
Nearly 77% of children receiving Hemlibra once weekly experienced zero treated bleeds Hemlibra once weekly reduced treated bleeds by 99% compared to prior bypassing agents in a prospective intra-pati
Nearly 77% of children receiving Hemlibra once weekly experienced zero treated bleeds Hemlibra once weekly reduced treated bleeds by 99% compared to prior bypassing agents in a prospective intra-pati
Longer-term follow-up data demonstrate sustained benefit of polatuzumab vedotin-based treatment in relapsed or refractory diffuse large B-cell lymphoma
Polatuzumab vedotin in combination with MabThera/Rituxan (rituximab) plus bendamustine more than doubled overall survival, compared to MabThera/Rituxan plus bendamustine alone in the phase Ib/II GO29365 study Polatuzumab vedotin has the potential to provide a promising new treatment option at first relapse Results from the GO29365 study, the first and only randomised study to suggest a survival benefit for patients not eligible for a haematopoie
Polatuzumab vedotin in combination with MabThera/Rituxan (rituximab) plus bendamustine more than doubled overall survival, compared to MabThera/Rituxan plus bendamustine alone in the phase Ib/II GO29365 study Polatuzumab vedotin has the potential to provide a promising new treatment option at first relapse Results from the GO29365 study, the first and only randomised study to suggest a survival benefit for patients not eligible for a haematopoie
Novartis announces FDA filing acceptance and Priority Review of AVXS-101, a one-time treatment designed to address the genetic root cause of SMA Type 1
The AVXS-101, now known as ZOLGENSMA (onasemnogene abeparvovec-xxxx) , filing is supported by data from the START trial which demonstrated a dramatic increase in survival and transformative improvement in achievement of developmental milestones compared to the natural history of SMA Type 1 SMA Type 1 is a progressive neuromuscular disease and the leading cause of genetic mortality in infants globally ZOLGENSMA represents the first in a propr
The AVXS-101, now known as ZOLGENSMA (onasemnogene abeparvovec-xxxx) , filing is supported by data from the START trial which demonstrated a dramatic increase in survival and transformative improvement in achievement of developmental milestones compared to the natural history of SMA Type 1 SMA Type 1 is a progressive neuromuscular disease and the leading cause of genetic mortality in infants globally ZOLGENSMA represents the first in a propr
Real-world data show Novartis drug Revolade improves outcomes for ITP patients compared to other second-line therapies
Revolade (eltrombopag) showed lower rate of bleeding-related episodes and similar rate of thrombotic events vs.
Revolade (eltrombopag) showed lower rate of bleeding-related episodes and similar rate of thrombotic events vs.
Novartis announces longer-term analyses from pivotal Kymriah trials that showed durable responses are maintained in patients with advanced blood cancers
In the updated analysis from ELIANA, Kymriah demonstrated an 82% remission rate within 3 months in pediatric patients with r/r ALL; relapse-free survival was 62% at 24 months, with median duration of
In the updated analysis from ELIANA, Kymriah demonstrated an 82% remission rate within 3 months in pediatric patients with r/r ALL; relapse-free survival was 62% at 24 months, with median duration of
Novartis announces new crizanlizumab (SEG101) data analysis in sickle cell disease, and investment in SENTRY clinical program
New post-hoc analysis of SUSTAIN study, presented at ASH 2018, highlights results among patients who were treated per protocol compared with all randomized patients Crizanlizumab, a monthly infusion
New post-hoc analysis of SUSTAIN study, presented at ASH 2018, highlights results among patients who were treated per protocol compared with all randomized patients Crizanlizumab, a monthly infusion
Last fall, EPFL introduced a new continuing education program whereby participants earn a Certificate of Open Studies (COS) - the only one of its kind in Switzerland. The first COSs were handed out at a ceremony this past Thursday. Switzerland's very first Certificates of Open Studies (COSs) were handed out this past Thursday at a ceremony at EPFL.
Ten projects awarded
ETH researchers had excellent results in the issuing of ERC grants: they were able to win 10 Consolidator Grants in the amount of 24 million Swiss francs for their research. Researchers from ETH Zurich have never before been able to win so many ERC Consolidator Grants in one round as they managed to this time.
ETH researchers had excellent results in the issuing of ERC grants: they were able to win 10 Consolidator Grants in the amount of 24 million Swiss francs for their research. Researchers from ETH Zurich have never before been able to win so many ERC Consolidator Grants in one round as they managed to this time.
Novartis announces EU approval of Gilenya for children and adolescents with MS, making it the first and only oral disease-modifying treatment for these patients in Europe
Approval based on landmark PARADIGMS study showing Gilenya (fingolimod) significantly reduced relapse rates by 82% vs interferon beta-1a; additionally, 85.7% of Gilenya patients were relapse-f
Approval based on landmark PARADIGMS study showing Gilenya (fingolimod) significantly reduced relapse rates by 82% vs interferon beta-1a; additionally, 85.7% of Gilenya patients were relapse-f
Start-up Switzerland in numbers
Where does Switzerland as a start-up location stand in international comparison? How has it developed? What are the strengths and weaknesses' Now, we have data-based answers to these questions.
Where does Switzerland as a start-up location stand in international comparison? How has it developed? What are the strengths and weaknesses' Now, we have data-based answers to these questions.
In a new study published in Science a team led by Prof. Petr Broz from the Department of Biochemistry identify a new mechanism to control immune cell death associated with inflammatory diseases, including sepsis, inflammatory bowel disease (IBD), and arthritis.
Novartis announces landmark EU approval for one-time gene therapy Luxturna to restore vision in people with rare inherited retinal disease
Luxturna* (voretigene neparvovec) is the first gene therapy to treat an inherited retinal disease, indicated for children and adults with vision loss caused by mutations in both copies of the RPE65 g
Luxturna* (voretigene neparvovec) is the first gene therapy to treat an inherited retinal disease, indicated for children and adults with vision loss caused by mutations in both copies of the RPE65 g
"Science Wire" gives access to latest science news from universities, research centers and R&D companies.Add this page to your bookmarks
